



Pharmaceutical 3D Printing of Personalized Medicine.

Corporate Presentation · October 2026

CSE: PHRM | OTCQB: PHRRF

IMPORTANT NOTICE

Forward-Looking Statements

This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation with respect to PharmaTher Holdings Ltd. (the "Company"). All information other than statements of historical fact — including statements regarding the Company's business strategy and the PERSONALIZ3D™ platform; the development, validation, regulatory approval, commercialization and adoption of the Company's product candidates, formulations, drug-delivery technologies, services and CraftMake™ distribution business; anticipated market growth; regulatory developments, including FDA rulemaking on compounded peptides, orphan-drug and rare pediatric disease designations and priority review vouchers; government preparedness programs; partnerships and collaborations; and the monetization of strategic assets — constitutes forward-looking information. Forward-looking information is based on the Company's current expectations, estimates, projections and assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. No assurance can be given that any of the events anticipated will transpire or occur, or if any of them do, what benefits the Company will derive from them. Product candidates described in this presentation are at a development stage. Compounded drugs are not FDA-approved. No peptide described as part of the Company's proprietary franchise may be lawfully compounded unless and until the FDA completes the applicable rulemaking. Program cost, timing and voucher-value figures are internal estimates. This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction. Market, industry and third-party data included in this presentation has not been independently verified by the Company. Readers are cautioned not to place undue reliance on forward-looking information and are encouraged to review the Company's public filings on SEDAR+ (www.sedarplus.ca) for a full discussion of risk factors.

WHO WE ARE

Pharmaceutical 3D printing for personalized medicine.



PLATFORM

PERSONALIZ3D™

GMP-ready pharma 3D printer · Proprietary delivery systems · Personalized medicines



PIPELINE

Proprietary products

Peptides · Psychedelics (Ketamine) · Rare diseases · Medical countermeasures




PARTNERING

Commercial readiness

CraftMake™ · CDMO & white-label · Product & IP licensing · National Emergency Network

PERSONALIZED™

*Any **dose**,*
*any **release**,*
*any **combination**,*
*any**where**.*



Q4 2026

503A product launches

50

CraftMake™ placements targeted in 12 months

1

National Emergency Network for medical countermeasures (i.e., pandemics, biodefence)

Q4 2028

rare pediatric NDA targeted — priority review voucher eligible (potential value US\$100–155M)

OUR MISSION

Medicine is made for everyone.

We make it for one.


THE OPPORTUNITY

The long tail of dose: mass manufacturing was never built to serve.

Conventional pharmaceutical manufacturing unable to serve distinct and fragmented populations economically

MASS MANUFACTURING

Millions of identical units. Fixed strengths. Central plants.



Personalized Peptides & Psychedelics

telehealth patients who need personal personalization



Rare diseases

Low volume, weight-banded doses (pediatrics)



Special access programs and Clinical trial supply

many strengths, a few hundred units each



National Emergency and Medical countermeasures

stockpile and special population supply




Discontinued medicines

volume never justified a production line

WHY PHARMACEUTICAL 3D PRINTING

The exact dose, for the specific patient, on-demand — economically.

Five things mass production can't do economically — and why each one creates value.



Sources: Craft Health platform specifications (±1% dose accuracy, room-temperature semi-solid extrusion); ASPR Industrial Base Assessment 2022. Graphics are illustrative.

OUR SOLUTION

PERSONALIZED^{ED}™ Pharmaceutical 3D Printing Platform.



PHARMATHER OWNS THE VALUE LAYER



Formulations and dosage-form designs



Analytical, stability and production data



Digital recipes, methods and protocols



Hardware, software integrations, regulatory filings and brands

HARDWARE PARTNER

CraftMake™ by Craft Health is already sold and operating in multiple markets.
PharmaTher is the exclusive North American distributor.




Images: Craft Health platform-capability imagery shared with PharmaTher under the companies' collaboration and distribution agreements. Recipe values are illustrative; ±1% reflects Craft Health system specifications.

Exclusive North American distributor of CraftMake™ pharmaceutical 3D platform.



Estimated more than 10,000 potential placement sites across all customer segments



CraftMake™

3D printing platform, by Craft Health

GMP-READY

HEAT-FREE · UV-FREE

±1% DOSE-WEIGHT PRECISION

WHAT WE DISTRIBUTE

- CraftMake™ 3D printing systems
- CraftControl™ software licences
- CraftBlends™ immediate-, sustained-release and chewable material delivery systems
- Spares, consumables and printheads
- Installation, training, validation support and annual service

SIGNIFICANCE

Every placement is infrastructure, not a one-time sale: it seeds recurring consumables, software and service revenue, and it is where PERSONALIZ3D™ formulations run.

Every placement instantly becomes part of the network for National Emergency and medical countermeasures (i.e., pandemics, biodefense, natural disasters).

CUSTOMER SEGMENTS



503A and 503B compounding pharmacies

~7,500 U.S. 503A pharmacies



Telehealth and digital health companies

A manufacturing layer for platforms that own the patient



CDMOs and pharma / biotech

Clinical supply, specialty production



Academic, government and hospital labs

R&D, National Emergency Preparedness

WHY NOW

Regulation, demand, technology and preparedness are converging.

US\$141B → US\$295B

Peptide therapeutics market,
2025 → 2033



REGULATION IS MOVING
TOWARD US

Six peptides recommended by FDA PCAC for 503A compounding in July 2026 and potentially five more in February 2027 – the pathway keeps extending.

Rare pediatric priority review vouchers reauthorized to September 2029.

FDA advanced-manufacturing designation signals support for distributed production.

US\$567B → US\$1.2T

Global personalized-medicine market,
2024 → 2033



DEMAND IS
FRAGMENTING

Telehealth is the fastest-growing route to the U.S. patient.

Children with rare diseases still split adult tablets.

US\$41B → US\$59B

Medical countermeasures market,
2025 → 2030



MEDICAL
COUNTERMEASURES ARE
GOING LOCAL

By executive order, the U.S. Strategic API Reserve will hold ingredients for ~26 critical drugs — doses must be made when needed.

ASPR is piloting point-of-need drug manufacturing; the FY2027 budget request seeks US\$327M (+US\$317M) to onshore supply.

The national stockpile holds adult strengths while CDC tells caregivers to crush tablets for children.



THE CATEGORY IS OPEN

FDA approved the first 3D-printed medicine.

Technology-led companies have proven medicines can be printed.

We believe no North American company has yet built a diversified product pipeline and partnering business on it.

PharmaTher intends to be that company.

Sources: Grand View Research (Peptide Therapeutics Market Report; Personalized Medicine Market Report); The Business Research Company, Medical Countermeasures Global Market Report 2026; FDA PCAC meeting July 23–24, 2026; Consolidated Appropriations Act 2026; FDA AMT designation program; Executive Order 14336 (Aug. 2025); ASPR Equip-A-Pharma (2025); ASPR FY2027 President's Budget Request; CDC, Preparing Doxycycline Hyclate for Non-Pill Swallowers. Market data not independently verified by the Company.

CSE: PHRM | OTCQB: PHRRF


BUSINESS MODEL

Two pillars. One platform.

WE OWN the products and placement infrastructure.

PILLAR 1 · PRODUCT PIPELINE

-  Personalized peptides — weight-loss, longevity, healing, etc
-  Rare pediatric diseases — priority review voucher-eligible NDAs
-  Ketamine —for telehealth and medical countermeasures
-  Medical countermeasures — National emergencies network nodes



WE OPEN the platform to partnerships.

PILLAR 2 · PARTNERING & TECHNOLOGY

-  CDMO, white-label, and clinical trial supply services
-  Product development and research collaborations
-  Product and technology licensing
-  Exclusive CraftMake™ distribution in North America
-  Access - Patient special access (rare diseases), Gov't preparedness
-  Strategic asset licensing — ketamine, cepharanthine

REVENUE STACK



Product sales



System
placements



Consumables &
service



Development fees



Licences &
royalties



Government
contracts



Voucher sales



Asset monetization

The pipeline creates proprietary value. Partnering creates reach, adoption and recurring revenue — and surfaces new products. Each feeds the other.

PRODUCT PIPELINE

Two pathways to market

Current focus: Peptides, Ketamine, and Rare diseases.



Bars show current development stage; timelines are internal estimates. 503A products are patient-specific compounded prescriptions prepared by a licensed pharmacy and are not FDA-approved. ODD = orphan drug designation; RPD = rare pediatric disease designation; NDA = new drug application.

PRODUCT SPOTLIGHT · SINGLE AND STACKABLE PROGRAMS

Peptide and wellness products.

Today’s 503A-ready peptides are prescribed and compounded through U.S. telehealth platforms, mostly as injections. PERSONALIZ3D™ prints them as precision-dosed oral forms — single peptides or stacked combinations in one unit.

503A-READY



CHEWABLE

NAD+

Cellular energy and longevity



LIQUID EMBEDDED CHEWABLE

Glutathione


Antioxidant · skin and detox wellness



MULTI-LAYER STACK

Sermorelin + NAD+ longevity stack

One unit replacing two products




SUBLINGUAL ODT

PT-141 (bremelanotide)

Sexual wellness · men's and women's health

PENDING FDA RULEMAKING



Coated core · gut release

DELAYED-RELEASE

BPC-157

Gut and tissue repair · lower-GI release



Two layers · one unit

BI-LAYER STACK

Wolverine stack

BPC-157 + TB-500 · tissue recovery

NUTRACEUTICAL



LIQUID CORE GUMMY

Nutraceutical gummy

Multi-active wellness · no prescription

NEXT WAVE ON FDA RULEMAKING BPC-157 · KPV · TB-500 · MOTS-c · Eptalon · Semax — recommended by FDA advisers July 2026; five more under review before Feb 2027.

Telehealth precedents: Hims & Hers Q2 2026 results and Aug 2026 statements (sermorelin, glutathione, NAD+ by year-end 2026; BPC-157 and five others pending FDA rulemaking); Strut Health, Luvo Health, Live Vital, Bodybuilding Health+, Tactus Health product pages (accessed Sept 2026). 503A eligibility reflects the current FDA framework (components of FDA-approved drugs or Category 1 bulk substances) and is verified per product before launch; oral formulations require PharmaTher validation and stability work. BPC-157 and TB-500 can be compounded only once FDA completes rulemaking adding them to the 503A bulks list (July 2026 PCAC votes are non-binding). The nutraceutical gummy would be sold as a dietary supplement, not a compounded drug. Compounded drugs are not FDA-approved; dose ranges and tablet diagrams are illustrative.

FDA pathway product with rare pediatric voucher potential.

Pharmaceutical 3D printing solves → Adult tablets cut for children, dose precision is the product.

TODAY



One adult strength, quartered at home

Dose accuracy: unknown. Every new strength is a separate campaign no manufacturer tools up for.

WITH PERSONALIZ3D™



5 kg 10 kg 15 kg 20 kg 30 kg

One validated recipe prints every weight band at ±1%. A new strength — or a titration series as the child grows — is a file change, not a factory change.

LEAD FDA-TRACK PROGRAM · 505(b)(1) · ORPHAN + PRIORITY REVIEW VOUCHER

Undisclosed compound · rare pediatric disease

NDA Q4 2028



Serious, early-onset and dosed by body weight — a dose that must change as the child grows



No FDA-approved product exists; today's treatment is improvised from unlicensed or chemical-grade material



Printed weight-banded, taste-masked chewable — dose-accurate units in place of hand-measured doses



Designations filed on published literature; objective endpoint supports a compact, single-arm program

PATH TO NDA

ODD + RPD designations	Pre-IND meeting	Clinical	NDA submission
Q1 2027	2027	2027–28	Q4 2028


One never-approved therapy, one printed weight-banded treatment — and a potential priority review voucher on approval. Further candidates are screened behind it.

Compound and indication undisclosed. Timelines and program costs are internal estimates subject to FDA feedback. Weight-band graphic is illustrative.

THE PRV OPPORTUNITY

Approval can earn a priority review voucher — a potential US\$100M+ asset.

WHAT RARE PEDIATRIC VOUCHERS HAVE SOLD FOR (US\$ MILLIONS, REPORTED)



HOW THE INCENTIVES WORK

- 1 Orphan Drug Designation**
7 years of market exclusivity, NDA fee waiver and a clinical-trial tax credit.
- 2 Rare Pediatric Disease designation**
A designated, never-approved active approved under a full NDA earns a voucher.
- 3 The Priority Review Voucher**
A transferable ticket to a 6-month FDA priority review of any future drug. Big pharma buys them; small companies sell them.

PharmaTher: lead rare pediatric NDA targeted Q4 2028 — a potential voucher on approval.

Sources: 21 USC 360ff; FDA OOPD; BioSpace "Priority Review Vouchers: By the Numbers" (Mar 2025); company press releases on each transaction. Voucher award and value are not assured; eligibility is determined at approval.

One ketamine formulation, two markets.



KETAMINE ODT

Printed dissolvable tablet

Dissolves in the mouth — no water, no needle.
Printed size sets the dose; the formulation stays the same.



10 mg




25 mg



50 mg



75 mg



100 mg

TELEHEALTH 10–100 mg in fine increments, titrated to each patient

MEDICAL COUNTERMEASURES weight bands, 25–100 mg



TELEHEALTH · 503A · Q1 2027

Precision-dosed dissolvable tablets

- ✓ 10–100 mg in fine titration increments at $\pm 1\%$ — personalized to patient and protocol
- ✓ Documented content uniformity and digital batch records for every dose
- ✓ Deployable through 503A compound pharmacies and telehealth partners



MEDICAL COUNTERMEASURES · DoD / BARDA / DRDC · NEXT

Non-injectable analgesia for mass-casualty and field care

- ✓ Weight-banded sublingual tablet or film, 25–100 mg — the same validated formulation
- ✓ No approved oral or transmucosal ketamine product exists today
- ✓ 505(b)(2) pathway; DoD / DHA and Canadian Forces Health Services potential lead sponsors and funding partners


Ketamine is the molecule we know.

FDA-approved ketamine ANDA developed and sold (Dec 2025, strategic rights retained) · KetaVault™ CMC, IND and orphan-designation data · Ketamine patch program

Compounded ketamine products are not FDA-approved. The MCM format would require a 505(b)(2) NDA with clinical studies and DEA registration at each manufacturing site. Ketamine ANDA transaction: PharmaTher press release, Dec 2, 2025. ODT graphic is illustrative; tablet sizes shown for a single formulation at constant thickness.

National Emergency Preparedness Node Network.

Potential for thousands of node locations at various organizations and institutions across the U.S. and Canada



26 drugs in the U.S. Strategic API Reserve with no finished-dose capability

~35,000 printed units per node per day

2025 ASPR, DARPA and FDA point-of-need manufacturing pilots — the door is open

Sold as readiness contracts — a complement to the stockpile, not a substitute. Sources: Executive Order 14336 (Strategic API Reserve, Aug 2025); ASPR / DARPA / FDA EQUIP-A-Pharma (2025). Throughput modelled at 60% utilization (10 printers, two shifts). Node locations are illustrative; FDA has not yet finalized a distributed-manufacturing framework.
CSE: PHRM | OTCQB: PHRRF

COMMERCIAL PARTNERING

Six business streams that feed each other — and build a moat.



Illustrative business model. Streams are at different stages; several are pre-revenue. Nodes require site qualification; readiness contracts are prospective. CraftMake™ is a Craft Health product; PharmaTher is its exclusive North American distributor.

Foundation: asset-light model.



Exclusive North American distributor

CraftMake™ systems, software, materials and service. Every placement seeds recurring revenue — and runs PERSONALIZ3D™ recipes.



Center of Excellence

U.S. National 503A compounding pharmacy with 26+ years of experience. Fulfills personalized prescriptions and hosts the first CraftMake™ placement.



GMP contract manufacturer

FDA-track and controlled-substance products for NDA grade manufacturing.

STRATEGIC ASSETS

Non-dilutive upside outside the core: ketamine and cepharanthine.

Revenue generating ANDA in Q1-2027. Rest for licensing, sale or spin-out.



Ketamine ANDA

FDA-approved ANDA sold to Caplin Point (Dec 2025); strategic rights retained.

>US\$25M

potential: milestones + 7-year profit share



KetaVault™

CMC package, INDs, protocols and orphan designations — a licensable gateway for ketamine programs.

5

orphan designations - ALS, CRPS, IRI organs, seizures, Rett syndrome



Ketamine patch

Microneedle patch; IND-enabling study complete; Phase 1-ready and available for partnering.

40 h

extended delivery demonstrated



KetaMist®

Needle-free, patient-controlled ketamine. Collaboration agreement (July 2026) toward an FDA pathway.

9,000+

patient treatments to date



Sairiyo Therapeutics

49% equity in a clinical-stage company developing a patented orally bioavailable cepharanthine.

US\$3.5M

U.S. Defense investment (Ebola)

Ketamine ANDA deal value is potential and subject to commercial performance (PharmaTher press release, Dec 2, 2025). KetaMist® is not FDA-approved; current use is off-label. Sairiyo: US patent 10,576,077.


How our revenue stacks — each layer builds on the last.

Same platform, more revenue The recipes and data behind our products extend to peptides, white-label lines, licensing and readiness contracts. Every placement & strategic assets keep paying A CraftMake™ sale brings recurring consumables, software and service — alongside our 503A products and CDMO work.	Approvals add step-change value A rare pediatric approval brings orphan exclusivity and a priority review voucher — potential US\$100M+.	Priority review voucher sale — potential US\$100M+ FDA-approved rare pediatric indication with orphan exclusivity
	Government national emergency readiness contracts	
	Technology licensing & royalties	
	White-label & wellness products	
	Peptide franchise	
Ketamine ANDA / strategic-asset monetization		
CDMO services		
Consumables, software & service		
CraftMake™ system placements		
Proprietary 503A products		
NOW · 0–12 MONTHS 5 LAYERS Ketamine ANDA sales; PERSONALIZ3D™ platform starts and recurs	NEXT · 1–3 YEARS 9 LAYERS Licensing, partners and contracts layer on	STEP-CHANGE · 3+ YEARS 11 LAYERS Approvals, vouchers and exclusivity

CSE: PHRM | OTCQB: PHRRF

MILESTONES

Prove. Build. Lead.



Milestones and timelines are internal targets and forward-looking statements; they may change. Compounded products are not FDA-approved.

OUR TEAM

Leadership across drug development, FDA approvals, commercialization, manufacturing and capital markets.



Fabio Chianelli

Founder, Chairman & CEO

25+ years in specialty life sciences and investing; founder of PharmaTher and Revive Therapeutics.



Carmelo Marrelli

Chief Financial Officer

Public-company finance and administration; principal of Marrelli Support Services since 2009.



Dr. Beverly J. Incledon

Director

30+ years in pharma and drug delivery; former EVP R&D at Ironshore Pharmaceuticals.



Carlo Sansalone

Director

Investor across biotech, technology and real estate; President at Sanscon.

COMPANY

Capital Structure

91,019,065

Issued and outstanding common shares

1,500,000

Stock options outstanding

~19%

Insider ownership

PHRM (CSE)

PHRRF (OTCQB)

SUMMARY

The opportunity in front of us.





Thank You

info@pharmather.com

PharmaTher Holdings Ltd.